ERBB2 and breast carcinoma: As the real-world evidence of first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer, median OS and PFS was 21.4 months (95% CI 19.8–22.7) and 8.6 months (95% CI 8.3–9.0 M), respectively.